| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
Apomorphine HCl hydrate is a novel and potent dopamine D2 agonist
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Medication Use During Lactation There is currently no information regarding the use of apomorphine during lactation. If a mother needs to use apomorphine, this is not a reason to stop breastfeeding. However, apomorphine inhibits the release of prolactin in animals and may interfere with the establishment of lactation. Especially when breastfeeding newborns or premature infants, other medications should be preferred. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. |
|---|---|
| Additional Infomation |
Apomorphine hydrochloride is the hydrochloride form of apomorphine, a derivative of morphine. It is a non-ergot dopamine agonist with high selectivity for dopamine D2, D3, D4, and D5 receptors. Apomorphine hydrochloride exerts its effects by stimulating dopamine receptors in the substantia nigra-striatal system, hypothalamus, limbic system, pituitary gland, and blood vessels. This can enhance motor function, inhibit prolactin release, and induce vasodilation and behavioral changes. Apomorphine hydrochloride is used to treat Parkinson's disease and erectile dysfunction. Additionally, apomorphine hydrochloride acts on chemoreceptor trigger zones and can be used as a centrally acting emetic for drug overdose. Morphine, a dopamine D2 receptor agonist, is a potent emetic and has been used to treat acute poisoning. It has also been used for the diagnosis and treatment of Parkinson's disease, but its adverse effects limit its application.
See also: Apomorphine (contains the active ingredient)...View more... Drug Indications Treatment of erectile dysfunction in men, i.e., the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. Uprima requires sexual stimulation to be effective. Treatment of erectile dysfunction in men, i.e., the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. Taluvian requires sexual stimulation to be effective. Treatment of erectile dysfunction in men, i.e., the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse. Ixense requires sexual stimulation to be effective. |
| Molecular Formula |
C34H38CL2N2O5
|
|---|---|
| Molecular Weight |
625.587
|
| Exact Mass |
321.113
|
| CAS # |
41372-20-7
|
| Related CAS # |
58-00-4;314-19-2 (HCl);41372-20-7 (HCl hydrate);41035-30-7 (S-isomer HCl); 39478-62-1 (S-isomer);
|
| PubChem CID |
107882
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.299 g/cm3
|
| Boiling Point |
473.4ºC at 760 mmHg
|
| Melting Point |
285-287 °C(lit.)
|
| Flash Point |
268.8ºC
|
| LogP |
3.525
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
43
|
| Complexity |
374
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CN1CCC2=C3C(=CC=C2)C4=C(C=CC(=C4O)O)C[C@H]31.CN1CCC2=C3C(=CC=C2)C4=C(C=CC(=C4O)O)C[C@H]31.Cl.Cl.O
|
| InChi Key |
CXWQXGNFZLHLHQ-DPFCLETOSA-N
|
| InChi Code |
InChI=1S/2C17H17NO2.2ClH.H2O/c2*1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2*2-6,13,19-20H,7-9H2,1H32*1H1H2/t2*13-/m11.../s1
|
| Chemical Name |
(R)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol hydrochloride hemihydrate
|
| Synonyms |
Apomorphine HydrochlorideApomorphine HClAPL-130277TAK-251TAK251TAK 251APL130277APL 130277KW-6500KW 6500KW6500ND-0701ND 0701ND0701Apomorphine HCl hydrate Apmorphine hydrochloride hemihydrate ApokynVR-004VR 004VR004VR-040VR 040VR040
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5985 mL | 7.9925 mL | 15.9849 mL | |
| 5 mM | 0.3197 mL | 1.5985 mL | 3.1970 mL | |
| 10 mM | 0.1598 mL | 0.7992 mL | 1.5985 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
